John A Latham insider trades: Alder Biopharmaceuticals (ALDR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
27 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 1, 2018 | ALDR | ↓ Sell10b5-1 | 25,002 | $13.42 | $336K | Direct | Nov 5, 2018 (4d) |
| Oct 1, 2018 | ALDR | ↓ Sell10b5-1 | 24,999 | $15.44 | $386K | Direct | Oct 3, 2018 (2d) |
| Sep 4, 2018 | ALDR | ↓ Sell10b5-1 | 24,999 | $17.99 | $450K | Direct | Sep 6, 2018 (2d) |
| Aug 1, 2018 | ALDR | ↓ Sell10b5-1 | 24,999 | $19.55 | $489K | Direct | Aug 2, 2018 (1d) |
| Jul 2, 2018 | ALDR | ↓ Sell10b5-1 | 24,999 | $15.48 | $387K | Direct | Jul 3, 2018 (1d) |
| Jun 1, 2018 | ALDR | ↓ Sell10b5-1 | 24,999 | $17.85 | $446K | Direct | Jun 5, 2018 (4d) |
| Dec 1, 2016 | ALDR | ↓ Sell10b5-1 | 3,636 | $22.78 | $83K | Direct | Dec 5, 2016 (4d) |
| Nov 9, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $30.18 | $302K | Direct | Nov 14, 2016 (5d) |
| Oct 3, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $31.32 | $313K | Direct | Oct 5, 2016 (2d) |
| Sep 1, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $32.49 | $325K | Direct | Sep 6, 2016 (5d) |
| Aug 1, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $31.19 | $312K | Direct | Aug 3, 2016 (2d) |
| Jul 27, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $30.14 | $301K | Direct | Jul 28, 2016 (1d) |
| Jun 1, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $30.02 | $300K | Direct | Jun 3, 2016 (2d) |
| May 31, 2016 | ALDR | ↓ Sell10b5-1 | 40,000 | $30.04 | $1.2M | Direct | Jun 1, 2016 (1d) |
| Jan 4, 2016 | ALDR | ↓ Sell10b5-1 | 10,000 | $31.41 | $314K | Direct | Jan 6, 2016 (2d) |
| Dec 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,550 | $37.24 | $169K | Direct | Dec 3, 2015 (2d) |
| Nov 2, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $33.69 | $153K | Direct | Nov 4, 2015 (2d) |
| Oct 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $32.26 | $147K | Direct | Oct 5, 2015 (4d) |
| Sep 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $38.52 | $175K | Direct | Sep 3, 2015 (2d) |
| Aug 3, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $45.62 | $207K | Direct | Aug 5, 2015 (2d) |
| Jul 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $51.13 | $232K | Direct | Jul 6, 2015 (5d) |
| Jun 4, 2015 | ALDR | ↓ Sell | 25,000 | $44.18 | $1.1M | Direct | Jun 8, 2015 (4d) |
| Jun 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $41.53 | $189K | Direct | Jun 3, 2015 (2d) |
| May 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $25.67 | $117K | Direct | May 5, 2015 (4d) |
| Apr 1, 2015 | ALDR | ↓ Sell10b5-1 | 19,045 | $29.54 | $563K | Direct | Apr 1, 2015 (0d) |
| Mar 2, 2015 | ALDR | ↓ Sell10b5-1 | 4,545 | $26.26 | $119K | Direct | Mar 4, 2015 (2d) |
| Jan 27, 2015 | ALDR | ↓ Sell10b5-1 | 15,045 | $28.33 | $426K | Direct | Jan 28, 2015 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About John A Latham's insider trades
John A Latham is Chief Scientific Officer at Alder Biopharmaceuticals (ALDR). Since Jan 27, 2015, John has reported no open-market purchases and 27 sales worth $9.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
26 sales (88% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (28 filings), grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALDR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.